Form 483

Aizant Drug Research Solutions Private Ltd. Form 483, 2020-01-24

FDA issued a Form 483 to Aizant Drug Research Solutions Private Ltd. on 2020-01-24 with 14 public-safe observations.

483· Form 483 issuedHuman Drugs14 observations

Aizant Drug Research Solutions Private Ltd. · Hyderabad, India · Issued January 24, 2020

Overview

  • 14 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

24 Jan 2020
21 CFR 211.170(b)

Reserve samples identified, representative, stored

Cited by Liming Zhang

24 Jan 2020
21 CFR 211.170(b)

Reserve samples identified, representative, stored

Cited by Liming Zhang

24 Jan 2020
21 CFR 211.186(b)(9)

Complete instructions, procedures, specifications et. al.

Cited by Liming Zhang

24 Jan 2020
21 CFR 211.186(b)(9)

Complete instructions, procedures, specifications et. al.

Cited by Liming Zhang

24 Jan 2020
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Liming Zhang

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.170(b)Cited across public-safe Form 483 observations2x
21 CFR 211.186(b)(9)Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.52Cited across public-safe Form 483 observations2x
21 CFR 211.63Cited across public-safe Form 483 observations2x
21 CFR 211.67(a)Cited across public-safe Form 483 observations2x
21 CFR 211.68(b)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 14 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere